High serum uric acid increases the risk for nonalcoholic fatty liver disease: A prospective observational study

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Xu, Chengfu ^a   Yu, Chaohui ^a   Xu, Lei ^a,b   Miao, Min ^b   Li, Youming ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NINGBO FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UREA; URIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINESE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; POPULATION RESEARCH; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD; FATTY LIVER; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; URIC ACID; YOUNG ADULT;

EID: 77955366821     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011578     Document Type: Article

References (33)

1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-31.
2. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, et al. (2005) Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22: 1141-1145.
3. Fan JG, Farrell GC (2009) Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50: 204-210.
4. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, et al. (2007) How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 22: 788-793.
5. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113-121.
6. Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219.
7. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395.
8. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, et al. (2005) Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43: 1060-1066.
9. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, et al. (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143: 722-728.
10. Roskams T, Yang SQ, Koteish A, Durnez A, De Vos R, et al. (2003) Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 163: 1301-1311.
11. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923.
12. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50: 1844-1850.
13. Hediger MA, Johnson RJ, Miyazaki H, Endou H (2005) Molecular physiology of urate transport. Physiology (Bethesda) 20: 125-133.
14. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, et al. (2005) Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69: 928-933.
15. Hjortnaes J, Algra A, Olijhoek J, Huisman M, Jacobs J, et al. (2007) Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol 34: 1882-1887.
16. Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120: 442-447.
17. Li Y, Xu C, Yu C, Xu L, Min M (2009) Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 50: 1029-1034.
18. Zhou M, Ma X, Li H, Pan X, Tang J, et al. (2009) Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol 161: 723-729.
19. Targher G, Bertolini L, Poli F, Rodella S, Scala L, et al. (2005) Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54: 3541-3546.
20. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, et al. (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44-52.
21. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, et al. (2007) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47: 412-417.
22. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283: 2404-2410.
23. Alberti K, Zimmet P, Shaw J (2006) Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabetic med 23: 469-480.
24. Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, et al. (2009) Microalbuminuria and risk of venous thromboembolism. JAMA 301: 1790-1797.
25. Jankowska EA, Rozentryt P, Ponikowska B, Hartmann O, Kustrzycka-Kratochwil D, et al. (2009) Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA 301: 1892-1901.
26. Hayden MR, Tyagi SC (2004) Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) 1: 10.
27. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, et al. (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106.
28. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359: 1811-1821.
29. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31: 361-362.
30. Harrison R (2002) Structure and function of xanthine oxidoreductase: where are we now. Free Radic Biol Med 33(6): 774-797.
31. Berry CE, Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555(Pt 3): 589-606.
32. Baskol G, Baskol M, Kocer D (2007) Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 40(11): 776-780.
33. Xu CF, Yu CH, Xu L, Sa XY, Li YM (2010) Hypouricemic therapy: a novel potential therapeutic option for nonalcoholic fatty liver disease. Hepatology, in press;doi:10.1002/hep.23798.